The self-administered COVID-19 sample collection kit offers consumers, employers, and government agencies increased capacity for home testing with the expertise of leading genomics and sequencing experts
ATLANTA, June 17, 2020 – BioIQ, a healthcare engagement and clinical adherence technology platform company, and Phosphorus, a leading genomics firm headquartered in New York City with a laboratory in Secaucus, New Jersey, announced today a partnership to provide an EUA-authorized at-home test kit that enables individual users to self-collect COVID-19 testing samples for laboratory processing. The joint solution includes Phosphorus’ easy-to-use, self-administered saliva collection kit and specimen return package, along with BioIQ’s health technology platform to support digital symptom and exposure assessment, contact tracing, and follow-up care navigation. Test results are delivered within 24-48 hours of receipt of lab sample.
Using a saliva-based collection method is simple and less intrusive than the prevalent swab-based methods, and this ease-of-use is a key characteristic to enabling the widespread and repetitive testing protocols proposed by experts to contain the COVID-19 pandemic. Phosphorus testing protocols use strict standards to ensure accurate and reliable test results. Phosphorus is one of the first to have received Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) to conduct a rigorous clinical agreement study above and beyond the synthetic sample performance study initially required by the FDA. The company is in full compliance with FDA Guidelines for Diagnostic Tests for Coronavirus Disease-2019 during a Public Health Emergency and submitted validation data under the FDA’s Emergency Use Authorization (EUA) authority.
“Additional RT-PCR COVID-19 testing capacity and convenience through home sample collection is a critical need for employers, health plans, and government agencies,” said BioIQ CEO Justin Bellante. “The partnership with Phosphorus adds the sophistication and validation of a leading genomics laboratory to our network and the expanded use of home sample collection and testing for COVID-19.”
The new at-home testing solution will be available as part of BioIQ’s back-to-work COVID-19 testing solution for employers. BioIQ enables employers to implement a thoughtful testing strategy that is mindful of critical roles and high-risk employees – all in support of the testing needs of employers, health plans, and government agencies. The partnership further enables BioIQ to connect employees, health plan members, and individuals with vital resources within the company’s extensive network of highly certified laboratories offering COVID-19 and other testing solutions.
“Phosphorus is excited about this partnership with BioIQ. We understand that testing is essential when it comes to re-opening the economy, and this alliance will ensure that people from coast to coast have access to safe, efficient and effective COVID testing,” said Alexander Bisignano, co-founder and CEO of Phosphorus. “Being a leading national genetics lab in addition to working firsthand with patients and studies in New York and New Jersey early in the pandemic have given us unique insight into real-world testing and validation.”
Organizations seeking assistance with COVID-19 testing initiatives can contact BioIQ at 888-818-1594 or visit https://www.bioiq.com/covid-19-solution/.
BioIQ is a healthcare engagement and clinical adherence technology platform company that is redefining the way payers, employers, and consumers navigate and connect with the US healthcare system. BioIQ leverages consumer analytics, real-time program intelligence, omnichannel personalized engagement strategies, and an extensive ecosystem of healthcare partners to provide a comprehensive view of individuals throughout their health journey and engage them to get testing and care that leads to healthier outcomes.
With more than a decade of healthcare industry experience and a first-of-its-kind health connectivity platform, BioIQ is uniquely positioned at the convergence of population health and the consumerization and retailization of healthcare to drive the shift to value-based care for payers and employers. Since 2005, BioIQ has launched thousands of successful health testing programs serving millions of participants. For more information, visit www.bioiq.com.